Alerts will be sent to your verified email
Verify Email
JENBURPH
|
Jenburkt Pharma
|
Medicamen Biotech
|
Albert David
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
18.49 % | 8.49 % | 11.47 % |
|
5yr Avg Net Profit Margin
|
18.1 % | 10.0 % | 11.31 % |
|
Price to Book
|
2.92 | 2.2 | 1.18 |
|
P/E
|
15.48 | 49.41 | 73.9 |
|
5yr Avg Cash Conversion Cycle
|
-32.02 Days | 13.14 Days | -77.77 Days |
|
5yr Average Interest Coverage Ratio
|
87.2 | 10.36 | 93.73 |
|
5yr Avg ROCE
|
24.44 % | 12.12 % | 14.69 % |
|
5yr Avg Operating Profit Margin
|
22.46 % | 16.84 % | 9.55 % |
|
5 yr average Debt to Equity
|
0.02 | 0.14 | 0.02 |
|
5yr CAGR Net Profit
|
14.21 % | -6.51 % | -4.92 % |
|
5yr Average Return on Assets
|
15.8 % | 5.75 % | 7.03 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.67 % | 40.46 % | 62.24 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.94 % | -3.14 % | 0.25 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Jenburkt Pharma
|
Medicamen Biotech
|
Albert David
|
|---|